19 Jan 2022 Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines Press Releases
19 Jan 2022 Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio Press Releases
19 Jan 2022 Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA Press Releases NASHVILLE, Tenn.–(
19 Jan 2022 Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma Press Releases LOS ANGELES–(
19 Jan 2022 Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) Press Releases BOTHELL, Wash.–(
19 Jan 2022 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib Press Releases …
19 Jan 2022 McKesson’s Board of Directors Elects James H. Hinton and Kathleen Wilson-Thompson as New Directors Press Releases IRVING, Texas–(
19 Jan 2022 IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer Press Releases WILMINGTON, Del.–(
19 Jan 2022 Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 Press Releases ALAMEDA, Calif.–(…
19 Jan 2022 IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years Press Releases WILMINGTON, Del.–(
